Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metoprolol succinate + candesartan versus metoprolol alone for regression of cardiac hypertrophy in hypertrophic cardiomyopathy
ChiCTR-IIR-17013661Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of metoprolol and candesartan in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Change in left ventricular mass from baseline. Started Oct 2018; status: recruiting.
02
Drugs
metoprololcandesartan
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on ChiCTR-IIR-17013661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013661.